4 Healthcare Stock Stories for Tuesday Investment Wellness

VIVUS, Inc. (NASDAQ:VVUS): Closing price $13.74

On Tuesday, Vivus said that its board has chosen Michael Astrue to serve as its Chairman, and Anthony Zook as its Chief Executive, effective immediately. Astrue formerly served as chief executive of Transkaryotic Therapies, Chairman of the Massachusetts Biotechnology Council, and Commissioner of Social Security. Zook formerly served as executive vice president, Global Commercial Operations for AstraZeneca, and president of Medimmune. Vivus recently began selling the obesity drug Qsymia (phentermine and topiramate extended-release capsules CIV) in the United States.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VVUS

Biogen IDEC Inc. (NASDAQ:BIIB): Closing price $222.65

Biogen said Monday that is looking into the death of a patient who had taken its new multiple sclerosis drug, Tecfidera. Company spokeswoman Kate Niazi-Sai reported that early indications suggest that the death is not likely to be related to the drug, but she had no immediate further details, commenting,”We are actively investigating to get a full understanding of what caused the death. The patient was not on Tecfidera at the time of death.” Tecfidera, introduced in April, is widely expected to become the number-one oral treatment for the disease, with yearly sales of over $3 billion.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BIIB

Verastem, Inc. (NASDAQ: VSTM): Closing price $15.91

Verastem has announced the confirmation of a complete response in an ongoing trial of VS-6063 (defactinib), in combination with paclitaxel dosed weekly. At Verastems Research and Development Day on July 11, Chief Medical Officer Dr. Horobin presented preliminary results describing a normalization of CA-125, which is a biomarker of ovarian cancer progression, and an initial radiologic complete response for one of the patients in the trial. Response Evaluation Criteria in Solid Tumors is the standard by which investigational drugs are examined for activity in oncology studies. Verastem is concentrated on discovering and developing drugs to treat cancer, via the targeted killing of cancer stem cells.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VSTM

AstraZeneca Group (NYSE:AZN): Closing price $50.86

Two additional AstraZeneca employees in Shanghai have now been questioned by Chinese police, subsequent to a sales representative being taken away for questioning earlier, according to the U.K. drug maker on Tuesday. The two employees are line managers of the sales representative who was detained on Friday, said a spokeswoman for the firm. One of the managers is continuing to cooperate with the Shanghai Public Security Bureau and their inquiries.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

AZN

Investing Insights: Can Celgene Continue Its Impressive Growth?